Allogeneic transplantation after PD-1 blockade for classic Hodgkin lymphoma Journal Article
| Authors: | Merryman, R. W.; Castagna, L.; Giordano, L.; Ho, V. T.; Corradini, P.; Guidetti, A.; Casadei, B.; Bond, D. A.; Jaglowski, S.; Spinner, M. A.; Arai, S.; Lowsky, R.; Shah, G. L.; Perales, M. A.; De Colella, J. M. S.; Blaise, D.; Herrera, A. F.; Shouse, G.; Spilleboudt, C.; Ansell, S. M.; Nieto, Y.; Badar, T.; Hamadani, M.; Feldman, T. A.; Dahncke, L.; Singh, A. K.; McGuirk, J. P.; Nishihori, T.; Chavez, J.; Serritella, A. V.; Kline, J.; Mohty, M.; Dulery, R.; Stamatoulas, A.; Houot, R.; Manson, G.; Moles-Moreau, M. P.; Orvain, C.; Bouabdallah, K.; Modi, D.; Ramchandren, R.; Lekakis, L.; Beitinjaneh, A.; Frigault, M. J.; Chen, Y. B.; Lynch, R. C.; Smith, S. D.; Rao, U.; Byrne, M.; Romancik, J. T.; Cohen, J. B.; Nathan, S.; Phillips, T.; Joyce, R. M.; Rahimian, M.; Bashey, A.; Ballard, H. J.; Svoboda, J.; Torri, V.; Sollini, M.; De Philippis, C.; Magagnoli, M.; Santoro, A.; Armand, P.; Zinzani, P. L.; Carlo-Stella, C. |
| Article Title: | Allogeneic transplantation after PD-1 blockade for classic Hodgkin lymphoma |
| Abstract: | Anti-PD-1 monoclonal antibodies yield high response rates in patients with relapsed/refractory classic Hodgkin lymphoma (cHL), but most patients will eventually progress. Allogeneic hematopoietic cell transplantation (alloHCT) after PD-1 blockade may be associated with increased toxicity, raising challenging questions about the role, timing, and optimal method of transplantation in this setting. To address these questions, we assembled a retrospective cohort of 209 cHL patients who underwent alloHCT after PD-1 blockade. With a median follow-up among survivors of 24 months, the 2-year cumulative incidences (CIs) of non-relapse mortality and relapse were 14 and 18%, respectively; the 2-year graft-versus-host disease (GVHD) and relapse-free survival (GRFS), progression-free survival (PFS), and overall survival were 47%, 69%, and 82%, respectively. The 180-day CI of grade 3–4 acute GVHD was 15%, while the 2-year CI of chronic GVHD was 34%. In multivariable analyses, a longer interval from PD-1 to alloHCT was associated with less frequent severe acute GVHD, while additional treatment between PD-1 and alloHCT was associated with a higher risk of relapse. Notably, post-transplant cyclophosphamide (PTCy)-based GVHD prophylaxis was associated with significant improvements in PFS and GRFS. While awaiting prospective clinical trials, PTCy-based GVHD prophylaxis may be considered the optimal transplantation strategy for this patient population. © 2021, The Author(s), under exclusive licence to Springer Nature Limited part of Springer Nature. |
| Journal Title: | Leukemia |
| Volume: | 35 |
| Issue: | 9 |
| ISSN: | 0887-6924 |
| Publisher: | Nature Publishing Group |
| Date Published: | 2021-09-01 |
| Start Page: | 2672 |
| End Page: | 2683 |
| Language: | English |
| DOI: | 10.1038/s41375-021-01193-6 |
| PUBMED: | 33658659 |
| PROVIDER: | scopus |
| DOI/URL: | |
| Notes: | Article -- Export Date: 1 October 2021 -- Source: Scopus |
Altmetric
Citation Impact
BMJ Impact Analytics
Related MSK Work